The ATLAS trial highlights the impact of implantable cardioverter defibrillator (ICD) leads on tricuspid regurgitation. Findings show that patients with transvenous leads experience worse outcomes related to tricuspid regurgitation compared to those with subcutaneous leads. Further research is needed to explore the implications of this relationship on patient health.
Read More
A study reveals that children with repaired tetralogy of Fallot experience reduced muscle strength, affecting their exercise performance. The correlation between muscle strength and exercise capacity emphasizes the need to consider muscle strength measurements in follow-up evaluations. These findings shed light on interpreting cardiopulmonary exercise test results for this patient population.
Read MoreA groundbreaking virtual roadmap tool is set to revolutionize percutaneous coronary intervention (PCI), promising increased procedural safety and reduced contrast volume.
Read More
The 2020 ESC guidelines offer a valuable tool for clinicians to determine thrombotic risk categories in non-ST-elevation ACS patients undergoing PCI. High-risk patients, as identified by the guidelines, are found to have a significantly increased bleeding risk. These findings pave the way for personalized precision medicine in managing this patient population.
Read More
A recent analysis of the TWILIGHT trial reveals that ticagrelor monotherapy after three months of dual antiplatelet therapy (DAPT) does not increase the risk of revascularization after percutaneous coronary intervention (PCI). In fact, monotherapy with ticagrelor shows a lower bleeding risk compared to continued DAPT. These findings provide insights into the potential benefits of ticagrelor monotherapy as a treatment strategy after PCI.
Read More